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Abstract
Human leucocyte antigen (HLA) class II molecules have been shown to be associated with
predisposition to rheumatoid arthritis (RA). We generated HLA-DR and DQ transgenic mice
that lacked endogenous class II molecules to study the interaction between the DR and DQ
molecules and define the immunologic mechanisms in rheumatoid arthritis. Using collagen-
induced arthritis (CIA) as an experimental model for inflammatory polyarthritis, we show that
both DQ and DR are involved in predisposition or resistance to arthritis. Our studies suggest
that polymorphism in DQB1 genes may determine predisposition to RA while the DRB1
polymorphism may dictate severity/protection of the disease. These mice provide powerful
tools to develop immunotherapeutic protocols.
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Introduction
Over a period of nearly two decades, several studies have
shown the association of various HLA class II molecules to
autoimmune diseases. Since the antigens are presented
as a MHC–peptide complex by antigen presenting cells, a
crucial role of HLA molecules is indicated in distinguishing
self and nonself. However, the pathophysiological role of
the HLA associations is poorly understood, although a
break in peripheral tolerance to distinguish self from
nonself has been suggested to be a critical step for devel-
opment of autoimmune disease. RA is an autoimmune dis-
order, leading to pathological damage to joints. Although
etiology and candidate antigen for RA is unknown, type II
collagen is a potential candidate since it is a major compo-
nent of joint articular cartilage, and both anti-type II colla-
gen antibodies and T cells specific for type II collagen
have also been detected in patients. Extensive documen-
tation exists linking HLA-DR molecules that share the HV3
region with the DRB1*0401 ‘shared epitope’ to suscepti-
bility to RA, although the mechanism is not clear. Recently,
it has been proposed that shared epitope might function
by determining the charge in peptide binding pockets [1].
Alternatively, this epitope might be responsible for shaping
the T cell repertoire in thymus, thereby determining the
outcome of disease when the relevant antigen is pre-
sented in periphery [2]. However, since DRB1 genes
occur in linkage with DQB1, it is difficult to rule out the
role of DQ molecule in disease development. Studies in
certain ethnic populations do suggest that DQ genes play
an important role in the disease process. Recent insights
into structure and function of MHC has enabled us to
better understand the interaction between MHC–peptide
complexes and T cell receptor along with other T cell
surface molecules. Since immune response to a particularArthritis Research    Vol 2 No 3 Taneja and David
antigen depends on the specificity and affinity of binding
to MHC and T cell recognition, it is important to define the
causative antigen presented by various DR and DQ mole-
cules. In humans, most of the studies have been carried
out in vitro using T cell lines and clones. Animal models of
autoimmunity are useful to study the immunopathogenetic
mechanisms in experimentally controlled conditions and
also to define the causative autoantigen, thereby helping
to develop therapeutic strategies for the disease.
CIA is an experimental model for RA that has been exten-
sively studied to define the pathogenic mechanisms. Immu-
nization of mice with heterologous type II collagen (CII)
leads to development of severe arthritis in susceptible
strains of mice [3]. Susceptibility to CIA is controlled by
polymorphism in H2A loci (homolog of DQ) and protection
by H2E loci (homolog of DR). To study the functions of
HLA class II molecules in disease induction and predispo-
sition, transgenic mice expressing HLA-DR and HLA-DQ
molecules have been developed. This decade has seen a
spate of research on these transgenic animals to explain
immunogenetic and immunological basis of the disease [4].
HLA-DR and HLA-DQ transgenic mice for
arthritis
In early studies, transgenic mice expressing an alpha or beta
chain from DR or DQ molecules were generated, which
showed that human class II chain could pair with mouse
class II chains and interact efficiently with mouse CD4,
although an antigen specific response could not be gener-
ated. Since antigen specific T cell response is important to
initiate disease, it was recovered in some studies by coex-
pressing huCD4 along with DR transgene [5]. However, a
lot of studies showed that requirement for species-matched
CD4 may not be absolute. The major hurdle for deciphering
the role of HLA in these transgenic mice was the presence
of endogenous mouse molecules. Introduction of HLA
transgenes in mice lacking endogenous mouse class II mol-
ecules [6] led to expression of HLA molecules on the cell
surface, which were functional. The potential value of HLA
transgenic mice as a model for RA was first illustrated in the
Abo.HLA-DQ8 transgenic mice. These mice expressed
functional DQ8 molecule (DQA1*0301, DQB1*0302), and
also restored maturation of CD4+ T cells [7••]. Since DQ8
occurs in linkage with DR4, it provided an attractive model
for defining the role of DQ molecules in arthritis. Immuniza-
tion of Abo.DQ8 with bovine type II collagen led to a severe
RA-like polyarthritis, thus establishing a novel approach to
studying pathogenic autoimmune response in mice express-
ing human MHC molecules. Also, these mice mount a
strong CD4-mediated and DQ-restricted T cell response
against immunizing antigen. This study clearly showed an
important role of DQ genes in predisposition to RA.
These findings led to a new hypothesis to explain the role
of shared epitope, suggesting that shared epitope shapes
the T cell repertoire in the thymus by serving as self-
peptide to the DQ molecule [2]. Thus, a high binding
peptide should negatively select autoreactive T cells, while
a low-affinity DR peptide would positively select potential
self-reactive T cells. This hypothesis was explored in
Abo.DQ8 mice, and the data showed that peptides
derived from RA-associated DRB1 alleles fail to induce a
DQ restricted response, while those from non-RA-associ-
ated alleles are highly immunogenic [8]. This again indi-
cated that DQ genes play a dominant role in
predisposition. The importance of polymorphism within the
DQ loci in determining susceptibility to arthritis was further
confirmed by studies in Abo transgenic mice expressing
DQ6 (DQA1*0103, DQB1*0601), an allele associated
with resistance to RA, which were also resistant to CIA.
To investigate the role of DRB1 molecules in RA, trans-
genic mice expressing functional DR molecules were gen-
erated. Introduction of H2E in Abo.DQ8 mice as well as
DR2 transgene in CIA susceptible H2Aq mice protected
them against arthritis. To address whether DRB1 polymor-
phism could modulate the response and outcome of
disease in Abo.DQ8 mice, transgenic mice expressing
DR3/DQ8/Abo (DRB1*0301, DQB1*0302) and
DR2/DQ8/Abo (DRB1*1501, DQB1*0302) were gener-
ated. DR2 has been shown to be associated with protec-
tion in some ethnic groups, while DR3 is a neutral allele in
human RA. The data on DQ/DR transgenic mice showed
that DRB1 polymorphism could modulate the disease in
Abo.DQ8 mice [9••]. Mice expressing DR2 were clearly
protected, while the presence of DR3 did not alter the
response and outcome of disease. Interestingly, the pro-
tected DR2\DQ8 mice respond to CII but secrete primar-
ily T helper 2 cytokines, while susceptible DR3\DQ8 mice
secrete higher amounts of T helper 1 and low amounts of
T helper 2 cytokines similar to DQ8 mice. These data
clearly showed that DRB1 polymorphism could modulate
the DQ restricted CIA. Thus, presence of DR2 could
change the cytokine profile from T helper 1 to T helper 2
type in DR2\DQ8 mice. Since cytokines are important
mediators for inflammation, this change in profile might
have been important for protection. This does indicate that
DRB1 can influence the T cell repertoire, and further
emphasizes the role of extended haplotypes in determin-
ing susceptibility to disease. Transgenic mice expressing
only Abo.DR2 or Abo.DR3 are resistant to disease, indi-
cating that the DR molecules alone were not sufficient for
initiation of disease. This again confirmed our notion that
both DR and DQ molecules are important in pathogene-
sis, where DQ genes may be the predisposing allele while
DR molecules may be modulating the disease by being
protective, neutral or exacerbative.
Studies using DR alleles associated with disease have
shown that DR1 and DR4 transgenic mice get disease
when mouse class II molecules are also expressed [10].http://arthritis-research.com/content/2/3/205
Mice expressing DR4 (DRB1*0401, DRA1*0101) suffer
only mild disease in those deficient in endogenous class II
molecules, even though they can mount DR4 restricted
response to DR4 binding proteins. However, introduction
of DRB1*0401 in H2Aq mice, resistant to porcine type II
collagen (PII), makes them susceptible to severe arthritis
induced by PII [11]. This showed that there is a specific
gene complementation between Aq and DR4 molecules,
leading to development of disease. This could involve pre-
sentation of antigens by autoreactive T cells, thus resulting
in production of cytokines, which is different to resistant
mice. This is supported by the fact that although many
nonsusceptible mice also respond to CII and produce
IFNg, the regulatory cytokines produced are different.
These data suggest that certain DR molecules can
present some antigens and cause mild arthritis, but
require the DQ molecule for severe disease. It has been
shown recently that RA-associated DQ molecules bind
many peptides derived from CII, while nonassociated DQ
molecules bind few peptides [12•]. Computer modeling of
the DQ6 molecule shows that it is a very compact mole-
cule with restrictive binding [13]. The P1 pocket of all RA-
associated DQ molecules is also similar [8]. Binding and
presentation of immunodominant CII peptide to CIA sus-
ceptible Aq and resistant Ap has been found to differ [14•],
which suggests that DQ polymorphism determines sus-
ceptibility. On the other hand, DR molecules can bind few
peptides derived from CII, irrespective of their association
with RA [15].
From the studies on DQ and DR transgenic mice, it can
be extrapolated that gene complementation or interaction
between DQ and DR molecules mediates susceptibility to
RA in the human. Depending on the haplotypes carried by
an individual, they could be susceptible to severe or mild
disease. A homozygous haplotype for predisposing DQ
and permissive DR will lead to severe disease. Also,
heterozygous RA-susceptible haplotypes will result in very
severe disease since there will be two predisposing DQ
molecules. However, one predisposing and one protective
haplotype should show less severity and low incidence.
These HLA transgenic mice have the potential to further
our insight into the function of HLA molecules in disease
pathology and development of therapeutic protocols.
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